The ETV6/ABL1 fusion transcript is thought to be a very rare aberration in hematopoietic malignancies. We describe two new cases of acute leukemia with the ETV6/ABL1 fusion, acute myeloid leukemia with eosinophilia (case 1) and B acute lymphoblastic leukemia (ALL) (case 2), screened by multiplex RT-PCR. The ETV6/ABL1 fusion was also confirmed by fluorescence in situ hybridization using a mixture of BCR/ABL1 and ETV6/RUNX1 probes. A thorough review of all published cases showed that all 7 reported ALL patients possess the type A ETV6/ABL1 fusion transcript, composed of the first 4 exons of ETV6 fused to the second exon of ABL1. The presence of the type A fusion transcript strongly implies ALL manifestation in ETV6/ABL1-positive hematologic malignancies as minor BCR breakpoint in BCR/ABL1-positive ALL.

Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM: The novel activation of ABL by fusion to an ETS-related gene, TEL. Cancer Res 1995;55:34–38.
Brunel V, Sainty D, Carbuccia N, Mozzicconacci M, Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-Pochitaloff M, Birg F: A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia 1996;10:2003.
Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Höglund M: BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 1997;20:299–304.
Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hählen K, Poppe B, Van Roy N, Marynen P, De Paepe A, Slater R, Speleman F: Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001;30:274–282.
Lin H, Guo JQ, Andreeff M, Arlinghaus RB: Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 2002;16:294–297.
Keung YK, Beaty M, Steward W, Jackle B, Pettnati M: Chronic myelocytic leukemia with eosinophilia, t(9;12) (q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 2002;138:139–142.
Barbouti A, Ahlgren T, Johansson B, Höglund M, Lassen C, Turesson I, Mitelman F, Fioretos T: Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 2003;122:85–93.
Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK: Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 2005;157:74–77.
Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S: Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 2008;47:919–921.
Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, Christacos NC, Mowrey PN, Witt MH, Hostetter A, Meloni-Ehrig AM: Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 2009;192:36–39.
Meyer-Monard S, Mühlematter D, Streit A, Chase AJ, Gratwohl A, Cross NC, Jotterand M, Tichelli A: Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 2005;19:1096–1099.
Mozziconacci MJ, Sainty D, Chabannon C: A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol 2007;82:688–689.
Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E: Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009;33:1144–1146.
Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996;16:4107–4116.
O’Brien SG, Vieira SA, Connors S, Bown N, Chang J, Capdeville R, Melo JV: Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 2002;99:3465–3467.
La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, Pelicci PG, Mecucci C: Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002;87:789–794.
Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA: Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet 2008;185:37–42.
Zuna J, Zaliova M, Muzikova K, Meyer C, Lizcova L, Zemanova Z, Brezinova J, Votava F, Marschalek R, Stary J, Trka J: Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer 2010;49:873–884.
Hannemann JR, McManus DM, Kabarowski JH, Wiedemann LM: Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 1998;102:475–485.
Million RP, Aster J, Gilliland DG, Van Etten RA: The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002;99:4568–4577.
Okuda K, Golub TR, Gilliland DG, Griffin JD: p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 1996;13:1147–1152.
Malinge S, Monni R, Bernard O, Penard-Lacronique V: Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 2006;25:3589–3597.
Pecquet C, Nyga R, Penard-Lacronique V, Smithgall TE, Murakami H, Régnier A, Lassoued K, Gouilleux F: The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation. Oncogene 2007;26:1577–1585.
Shaffer LG, Slovak ML, Campbell LJ: ISCN 2009. An International System for Human Cytogenetic Nomenclature. Basel, Karger, 2009.
Bohlander SK: Fusion genes in leukemia: an emerging network. Cytogenet Cell Genet 2000;91:52–56.
Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD: Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2001;31:134–142.
Tosi S, Hughes J, Scherer SW, Nakabayashi K, Harbott J, Haas OA, Cazzaniga G, Biondi A, Kempski H, Kearney L: Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003;38:191–200.
Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, Wang W, Li MY, Han XP, Sun JZ, Wang LL, Yu L: Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol 2012;91:1235–1243.
Park J, Kim M, Lim J, Kim Y, Han K, Lee J, Chung NG, Cho B, Kim HK: Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet Cytogenet 2009;19:102–105.
Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA: A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004;24:4685–4695.
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947–4952.
Okuda K, Weisberg E, Gilliland DG, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440–2448.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.